Supporting Our Colleagues: Easing the Burden of Referrals for CAR-T in Aggressive B-cell Lymphomas

Course Description

CAR T-cell therapy is a major advance in the treatment of individuals with non-Hodgkin lymphoma, especially for adult patients with relapsed or refractory large B-cell lymphoma. Several CAR-T therapies are now approved for second-line treatment, and data regarding their efficacy, safety, and real-world outcomes continue to emerge. Collaboration among hematologic oncology clinicians is needed to ensure that appropriate patients are referred for evaluation for CAR-T therapy earlier in their treatment journey, potentially offering them a better chance for lasting remission or even a cure.
During Supporting Our Colleagues: Easing the Burden of Referrals for CAR-T in Aggressive B-cell Lymphomas, expert cell therapists and a community oncologist, along with several special guests, will highlight the clinical implications of the most recent data on CAR-T therapy, explore referring clinicians’ misperceptions about access to and logistics associated with therapy, and provide practical tips to help cell therapists collaborate more effectively with referring colleagues to optimize shared care.
This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.

Other Courses in this Series

Other Courses That May be of Interest